It has been a volatile year for the biotech.

While PFS was not achieved in BioNTech’s cancer vaccine trial, there is still a chance for success with OS.

While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 ...

A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna ...

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, ...

After BioNTech (BNTX) announced its fixed combination vaccine, BNT113, missed one of its primary endpoints of improved progression free survival when combined with ...

A phase 2/3 trial of BioNTech's immunotherapy for head and neck cancer, BNT113, has failed to meet its objective, but the ...

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BioNTech recieved a 95 million euro ($110 million) boost from two EU groups that will go toward expanding production of mRNA vaccines in Africa using its modular BioNTainers. (BioNTech) As BioNTech ...

BioNTech had little to say about its pipeline progress on Monday. But it did report COVID vaccine sales which more than doubled analyst consensus. (Photo by Sean Gallup/Getty Images) BioNTech reported ...